Vanguard Global Advisers
FLNA

Vanguard Global Advisers’s Filana Therapeutics FLNA Stock Holding History

Vanguard Global Advisers’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Hold
15,897
– – ﹤0.01% 3348
2026
Q1 		$26.9K Buy
+15,897
New +$32.7K ﹤0.01% 3233

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Vanguard Global Advisers's FLNA Position: Q2 2026 in Review

Vanguard Global Advisers held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 15,897 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Vanguard Global Advisers first reported a position in FLNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $26.9K in Q1 2026. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Vanguard Global Advisers held 15,897 shares of Filana Therapeutics worth $18.9K as of Q2 2026.
  • Vanguard Global Advisers left its Filana Therapeutics share count unchanged in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3348 holding.
  • Vanguard Global Advisers first reported a position in Filana Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Filana Therapeutics position peaked at $26.9K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.